[go: up one dir, main page]

MX2013003764A - Metodos de elaboracion de fenilacetato de l-ornitina. - Google Patents

Metodos de elaboracion de fenilacetato de l-ornitina.

Info

Publication number
MX2013003764A
MX2013003764A MX2013003764A MX2013003764A MX2013003764A MX 2013003764 A MX2013003764 A MX 2013003764A MX 2013003764 A MX2013003764 A MX 2013003764A MX 2013003764 A MX2013003764 A MX 2013003764A MX 2013003764 A MX2013003764 A MX 2013003764A
Authority
MX
Mexico
Prior art keywords
phenyl acetate
making
methods
ornithine phenyl
ornithine
Prior art date
Application number
MX2013003764A
Other languages
English (en)
Other versions
MX360062B (es
Inventor
Jim Behling
Christine Henderson Dougan
Stephen William Watt
Peter Manini
Attilia Figini
Keith H Anderson
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Publication of MX2013003764A publication Critical patent/MX2013003764A/es
Publication of MX360062B publication Critical patent/MX360062B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen en la presente los procesos para elaborar el fenilacetato de L-ornitina. El proceso puede incluir por ejemplo, entremezclar una sal de haluro de Lornitina con el fenilacetato de plata. El proceso puede también incluir formar una sal de fenilacetato in situ. La presente solicitud también se refiere a diversas composiciones obtenidas a partir de estos procesos, incluyendo las formas cristalinas.
MX2013003764A 2010-10-06 2011-10-05 Metodos de elaboracion de fenilacetato de l-ornitina. MX360062B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39058510P 2010-10-06 2010-10-06
PCT/US2011/054983 WO2012048043A1 (en) 2010-10-06 2011-10-05 Methods of making l-ornithine phenyl acetate

Publications (2)

Publication Number Publication Date
MX2013003764A true MX2013003764A (es) 2013-05-20
MX360062B MX360062B (es) 2018-10-22

Family

ID=45928120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003764A MX360062B (es) 2010-10-06 2011-10-05 Metodos de elaboracion de fenilacetato de l-ornitina.

Country Status (16)

Country Link
US (2) US8946473B2 (es)
EP (1) EP2625162B1 (es)
JP (1) JP6087284B2 (es)
KR (1) KR101888215B1 (es)
CN (1) CN103502203B (es)
AU (1) AU2011312042B2 (es)
BR (1) BR112013008054B1 (es)
CA (1) CA2813563C (es)
EA (1) EA028395B1 (es)
ES (1) ES2720148T3 (es)
IL (1) IL225512A (es)
MX (1) MX360062B (es)
NZ (1) NZ609191A (es)
SG (1) SG189231A1 (es)
TR (1) TR201903978T4 (es)
WO (1) WO2012048043A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1824563T3 (pl) 2004-11-26 2010-07-30 Ucl Business Plc Kompozycje zawierające ornitynę i fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej
SMT201700601T1 (it) 2009-04-03 2018-03-08 Ocera Therapeutics Inc L-ornitina fenilacetato e metodi per la sua fabbricazione
MX2011013129A (es) 2009-06-08 2012-03-14 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
CN103502203B (zh) 2010-10-06 2016-09-07 欧塞拉治疗有限公司 制备l-鸟氨酸苯基乙酸盐的方法
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
ES2944311T3 (es) * 2015-04-20 2023-06-20 Ocera Therapeutics Inc Formulaciones de fenilacetato de L-ornitina
AU2016308641B2 (en) 2015-08-18 2022-02-03 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
RU2018113801A (ru) * 2015-11-13 2019-12-16 Осера Терапьютикс, Инк. Составы l-орнитин фенилацетата
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
EP3621947A4 (en) * 2017-05-11 2021-03-10 Ocera Therapeutics, Inc. L-ORNITHINE PHENYLACETATE MANUFACTURING PROCESSES
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
WO2020227516A1 (en) 2019-05-09 2020-11-12 Ocera Therapeutics, Inc. Methods of assessing and treating hepatic encephalopathy
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (es) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
US4100293A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
DE4020980C1 (es) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
DK0659150T3 (da) 1992-09-09 1997-09-29 Fisons Plc Farmaceutisk emballage.
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) * 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US6083953A (en) 1994-07-28 2000-07-04 Syntex (U.S.A.) Inc. 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
AU2251897A (en) 1996-02-13 1997-09-02 Trustees Of The University Of Pennsylvania, The Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
WO2000071151A1 (en) 1999-05-21 2000-11-30 Takeda Chemical Industries, Ltd. Liver function controlling agents
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
US20040192751A1 (en) 2001-03-15 2004-09-30 Takeshi Abe Amino acid composition for ameliorating liver failure
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
AU2003261825A1 (en) 2002-08-30 2004-03-19 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) * 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005108339A2 (en) 2004-05-06 2005-11-17 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
JP2008511611A (ja) 2004-08-30 2008-04-17 ルナメツド・インコーポレーテツド 治療用４−フェニル酪酸制御放出製剤
PL1824563T3 (pl) 2004-11-26 2010-07-30 Ucl Business Plc Kompozycje zawierające ornitynę i fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej
HRP20140476T1 (hr) 2005-11-17 2014-07-18 Silverstone Pharma Est. Stabilni oblik amorfnih soli perindoprila, postupak njihove pripreme, posebno industrijske pripreme i njihova uporaba u lijeäśenju hipertenzije
CN201421432Y (zh) * 2009-02-20 2010-03-10 山东师范大学 一种相干衍射成像处理装置
SMT201700601T1 (it) 2009-04-03 2018-03-08 Ocera Therapeutics Inc L-ornitina fenilacetato e metodi per la sua fabbricazione
MX2011013129A (es) 2009-06-08 2012-03-14 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
CN103502203B (zh) 2010-10-06 2016-09-07 欧塞拉治疗有限公司 制备l-鸟氨酸苯基乙酸盐的方法

Also Published As

Publication number Publication date
BR112013008054B1 (pt) 2019-04-09
CA2813563A1 (en) 2012-04-12
IL225512A0 (en) 2013-06-27
EA201390403A1 (ru) 2013-09-30
JP2013542935A (ja) 2013-11-28
US20150133684A1 (en) 2015-05-14
EA028395B1 (ru) 2017-11-30
NZ609191A (en) 2015-06-26
US8946473B2 (en) 2015-02-03
US9260379B2 (en) 2016-02-16
AU2011312042A1 (en) 2013-05-02
AU2011312042B2 (en) 2015-08-20
CA2813563C (en) 2019-02-26
JP6087284B2 (ja) 2017-03-01
US20130211135A1 (en) 2013-08-15
CN103502203B (zh) 2016-09-07
CN103502203A (zh) 2014-01-08
EP2625162A4 (en) 2014-06-25
WO2012048043A1 (en) 2012-04-12
MX360062B (es) 2018-10-22
EP2625162A1 (en) 2013-08-14
KR20140053807A (ko) 2014-05-08
ES2720148T3 (es) 2019-07-18
IL225512A (en) 2017-12-31
KR101888215B1 (ko) 2018-09-20
EP2625162B1 (en) 2019-03-13
SG189231A1 (en) 2013-05-31
TR201903978T4 (tr) 2019-04-22
BR112013008054A2 (pt) 2016-06-14

Similar Documents

Publication Publication Date Title
MX2013003764A (es) Metodos de elaboracion de fenilacetato de l-ornitina.
WO2011119004A3 (en) Method of producing d-psicose crystals
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
EA201291470A1 (ru) Замороженное кондитерское изделие
WO2011138281A3 (de) Verfahren zur herstellung von dithiin-tetracarboxy-diimiden
UA107865C2 (ru) Гетероциклические карбоксамиды
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
HK1202549A1 (en) Donepezil pamoate, preparation method and its use
WO2012138147A3 (en) 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid crystalline form and the producing method thereof
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
MX2012001876A (es) Composicion de sal.
SG11201402949RA (en) Process for producing nutrient composition
GEP201606569B (en) Urea finishing method
HK1199896A1 (en) Novel compositions for producing cast polyamides
EP2883870B8 (en) Method for producing 1,4-benzoxazine compound
IL227592A0 (en) A method for making 2,2-difluoroethylamine starting from 2,2-difluoro-1-chloroethane
WO2012140490A3 (en) Processes for preparing pitavastatin calcium
MX2013004878A (es) N-hetarilmetil pirazolilcarboxamidas.
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
EP2663546A1 (fr) Procede de production de composes nitrile-acide gras
WO2009122429A3 (en) Crystalline oxybutynin and process for preparing the same
AU2012248013B2 (en) Intermediate for synthesizing caspofungin and preparation method therefor
MX363944B (es) Método de preparación de los compuestos de ceramidas de alfa-galactosilo.
WO2013072938A3 (en) Process for the preparation of roflumilast

Legal Events

Date Code Title Description
FG Grant or registration